arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Protara Therapeutics, Inc.

TARA

$4.12 ▲ +0.02 (+0.49%) at close

15 Visible periods

22 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Bearish

auto_awesome

Analytical Summary

Protara Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $176.5M

Dividend Yield —

Revenue Growth —

Op. Margin None

ROIC -26.0% ↘

FCF / Share $-1.32 ↗

Trailing P/E —

Price / Book 1.1x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

15-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-57.44M

↓ -28.8% —

FCF / Share Free cash flow per share

$-1.32

↑ +24.3% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns →

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗	FY 2011 Dec 31, 2011 10-K ↗
EPS Growth YoY (%)	38.2% Excellent → Excellent Stable Year-over-year change in earnings per share Optimal: > 10%	39.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	39.1% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—	—	—	—	—	—
Net Income Growth YoY (%)	-28.8% Weak ↓ Weak Declining Year-over-year change in net income	-10.3% Weak ↑ Weak Improving Year-over-year change in net income	38.7% Excellent ↑ Excellent Improving Year-over-year change in net income	-39.6% Weak ↑ Weak Improving Year-over-year change in net income	-39.1% Weak ↑ Weak Improving Year-over-year change in net income	-333.9% Weak ↓ Weak Declining Year-over-year change in net income	62.2% Excellent ↑ Excellent Improving Year-over-year change in net income	30.8% Excellent ↑ Excellent Improving Year-over-year change in net income	-5.0% Weak ↑ Weak Improving Year-over-year change in net income	-33.4% Weak ↑ Weak Improving Year-over-year change in net income	-539.6% Weak ↓ Weak Declining Year-over-year change in net income	57.8% Excellent Excellent Year-over-year change in net income	0.7% Caution Caution Year-over-year change in net income	—	—
FCF Growth YoY (%)	24.3% Good ↑ Good Improving Year-over-year change in free cash flow	47.5% Excellent Excellent Year-over-year change in free cash flow	-40.6% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗	FY 2011 Dec 31, 2011 10-K ↗
Operating Margin (%) (%)	—	—	—	—	—	—	—	—	—	—	—	-257.1% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1814%)	—	—	—
Profit Margin (%) (%)	—	—	—	—	—	—	—	—	—	—	—	-113.4% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1045%)	—	—	—
FCF / Net Income (x)	0.98x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.40x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.74x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.71x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.70x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.13x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.75x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.84x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗	FY 2011 Dec 31, 2011 10-K ↗
Return on Invested Capital (%)	-26.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-23.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-50.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-51.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-23.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-13.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	290.7% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-82.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-69.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-59.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-26.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-7.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	5.6% Caution Caution Return earned on debt + equity capital invested Optimal: > 10%	7.3% Fair Fair Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-30.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-27.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-55.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-59.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-27.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-17.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-640.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-90.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-69.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-66.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-30.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-8.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	-125.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-29.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-295%)	-26.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-278%)	-59.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-494%)	-64.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-531%)	-29.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-295%)	-17.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-214%)	—	-101.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-776%)	-86.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-675%)	-74.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-595%)	-33.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-325%)	-4.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-127%)	7.9% Caution Caution Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-48%)	9.2% Caution Caution Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-39%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗	FY 2011 Dec 31, 2011 10-K ↗
Interest Coverage (x)	—	—	—	—	—	-1013.06x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	—	-8.84x Weak Weak Operating income divided by interest expense Optimal: > 5x	-8.27x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—
Net Debt (USD)	$-49.66M	$-162.80M	$-39.59M	$-24.13M	$-35.72M	$-168.60M	$-564.00K	$-19.37M	$-21.17M	$-36.39M	$-40.03M	$-68.84M	$-2.79M	$-2.41M	$-3.27M

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗	FY 2011 Dec 31, 2011 10-K ↗
Basic EPS, GAAP (USD)	$-1.34	$-2.17	$-3.57	$-5.86	—	—	—	—	—	—	—	—	—	—	—
Free Cash Flow per Share (USD)	$-1.32	$-1.74	$-3.32	$-2.36	—	—	—	—	—	—	—	—	—	—	—
Book Value per Share (USD)	$3.67	$4.77	$6.01	$9.06	$14.41	$17.77	$-0.81	$1.06	$1.97	$2.32	$3.84	$5.01	$-418.97	—	—
Tangible Book Value per Share (USD)	$3.67	$4.77	$6.01	$9.06	$11.78	$15.14	$-0.81	$1.06	$1.97	$2.32	$3.84	$5.01	$-418.97	—	—
Basic Weighted Avg Shares (shares)	42.84M	20.59M	11.33M	11.26M	—	—	—	—	—	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗	FY 2011 Dec 31, 2011 10-K ↗
Working Capital (USD)	$148.56M	$161.19M	$62.56M	$80.41M	$88.81M	$166.52M	$-2.59M	$20.16M	$34.24M	$37.68M	$62.48M	$82.26M	$-4.44M	—	—
Total Equity (USD)	$196.41M	$167.13M	$68.32M	$102.08M	$161.91M	$199.24M	$-2.13M	$20.44M	$34.74M	$38.44M	$63.41M	$82.46M	$-100.51M	$-86.66M	$-72.66M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗	FY 2011 Dec 31, 2011 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	—	—	—	—	—	—	—	—	—	$2.95M	—	—	—
Depreciation Expense (USD)	$362.00K	$332.00K	$341.00K	$248.00K	$117.00K	$103.00K	$16.00K	$115.00K	$148.00K	$123.00K	$57.00K	$30.00K	$27.00K	$57.00K	—
Net Income, GAAP (USD)	$-57.44M	$-44.60M	$-40.42M	$-65.95M	$-47.25M	$-33.98M	$-7.83M	$-20.73M	$-29.96M	$-28.53M	$-21.38M	$-3.34M	$-7.91M	$-7.97M	—
Operating Cash Flow (USD)	$-56.37M	$-35.81M	$-37.56M	$-26.46M	$-34.50M	$-23.41M	$-5.01M	$-23.23M	$-22.35M	$-23.69M	—	—	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 15 years · 54 quarters

Protara Therapeutics, Inc.

Analytical Summary

15-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare TARA with peers